Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
KA Imaging Expands Global Footprint
KA Imaging announced regulatory approvals for its Reveal Mobi Pro and Mobi Lite mobile X‑ray systems in Hong Kong and Australia, expanding its clinical footprint in Asia‑Pacific. The company also launched a partnership with Scintica to deliver its 3‑D X‑ray platform to North American research labs, broadening its reach into pre‑clinical and materials science applications. CEO Amol Karnick highlighted growing demand across hospitals, research, security, pharmaceuticals and electric‑vehicle sectors, underscoring a shift toward portable, information‑rich imaging solutions.
Rox Heart Radio: The 2026 Dyslipidemia Guidelines
In a recent Rox Heart Radio episode, cardiologists Roxana Mehran and Ann Marie Navar dissect the 2026 dyslipidemia guidelines. The conversation spotlights tighter LDL‑cholesterol targets, routine Lp(a) screening, and expanded use of coronary artery calcium (CAC) scoring for risk stratification. They...
WSJ Defends Replimune Drug Amid Mounting Criticism
@WSJ is not giving up the fight for Replimune's cancer drug. Second CRL draws another rebuke and a direct attack on @MartyMakary (Prasad gets another swipe as well, but he's about out the door now.) I often disagree with the...
CMS Establishes New Billing Code for AI-Driven Calcium Analysis on CT Scans
The Centers for Medicare & Medicaid Services (CMS) announced a new national billing code under the Hospital Outpatient Prospective Payment System, effective April 1, 2026, for AI-driven analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC) on chest CT scans....
AMA Launches New Surveys to Pinpoint Physician Burnout Drivers
The American Medical Association has unveiled a new suite of well‑being surveys designed to uncover the specific drivers of physician burnout. The initiative, part of the AMA’s Organizational Biopsy® program, seeks to give health systems granular insight into stressors affecting...
Life Biosciences Prepares First Human Trial of Partial Cellular Reprogramming for Glaucoma
Life Biosciences, co‑founded by David Sinclair, is preparing to launch the first human trial of partial cellular reprogramming, targeting retinal nerve cells in glaucoma patients. The study will use a three‑factor gene‑delivery system that can be switched on and off...
Novo Nordisk Teams Up with OpenAI to Fast‑Track Obesity Drug Development
Novo Nordisk announced a strategic partnership with OpenAI to embed advanced AI across its research pipeline, aiming to shorten development time for obesity and diabetes treatments. The deal, disclosed on April 14, sent Novo’s shares up 2.8% and underscores a...
Obsidian, Galera to Advance Cell Therapy Following Reverse Merger
Obsidian Therapeutics will go public on Nasdaq via a reverse merger with Galera Therapeutics, creating a combined entity focused on OBX-115, a tumor‑infiltrating lymphocyte (TIL) cell therapy. OBX-115 is in mid‑stage melanoma and early‑stage lung‑cancer trials and is designed to...
Germany's Health Reform Aims to Save €20 Billion, Triggers Insurer Backlash
Germany’s federal health‑care reform plan seeks to trim €20 billion from the system by capping doctor fees, hospital spending and drug co‑payments. Health‑insurance leaders and opposition parties warn the measures will shift costs onto patients, igniting a political showdown over the...
BMS Makes a Beeline, Bringing 5 Assets to Biotech's $300M Precision Immunology Debut
Bristol Myers Squibb has spun out a new biotech, Beeline Medicines, backed by $300 million from Bain Capital and an initial portfolio of five assets. The company, led by former SpringWorks CEO Saqib Islam, will focus on precision therapies for autoimmune...
Only 25% of GLP‑1 Users Stay on Treatment After One Year, 74% Plan to Restart
A JAMA‑published analysis of insurance claims shows fewer than 25% of patients stay on GLP‑1 drugs such as Ozempic and Zepbound after 12 months. A separate Kantar survey reveals that 74% of those who stop intend to resume, prompting clinicians...
Teva Launches “Home Ground” Online Resource for People Living with Schizophrenia and Their Care Partners
Teva Pharmaceuticals has launched Home Ground, a free online community for people living with schizophrenia and their care partners. The platform, built with input from patients and caregivers, offers symptom‑tracking worksheets, emotional‑wellness videos, independent‑living toolkits, physical‑health checklists, and both virtual...
STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More
U.S. FDA has asked Eli Lilly to provide additional safety data on its newly approved obesity drug Foundayo, mandating post‑marketing trials for cardiovascular events, delayed gastric emptying, and a lactation study. The pill, a GLP‑1 agonist, received accelerated approval through the...
Replimune Shares Tumble 64% After FDA Issues Second CRL on RP1 Vaccine
Replimune's shares dropped about 64% on April 10 after the FDA issued a second Complete Response Letter rejecting the RP1 vaccine. The setback forces the company into job cuts, raises questions about its pivotal IGNYTE‑3 trial, and slashes analyst price...
Briya Hits 120m Patient Journeys Milestone
Briya announced its global data network now spans over 120 million patient journeys, integrating records from the United States, European Union, Latin America, the United Kingdom, Asia and the Middle East. The expansion adds 3 million UK longitudinal records and broadens its...
The Medical Practice Marketing Metrics that Actually Matter
Physician practices often receive glossy marketing reports filled with impressions, reach and click‑through rates, yet they lack answers to the core question: how many new patients did the spend generate? Uday Rajaram argues that only four metrics—cost per lead, lead‑to‑appointment conversion...
Eight Allergy Companies to Watch in 2026
The allergy‑treatment landscape is moving from symptom relief to disease‑modifying therapies, with eight biotech firms leading the charge in 2026. Allergy Therapeutics secured German approval for its short‑course Grassmuno vaccine, while Aravax bolstered its board ahead of a phase 3 launch...
Community Response Teams: Extending the Rapid Response Model to Outpatient Care
Community response teams (CRTs) adapt hospital rapid‑response principles for managed‑care settings, using predictive analytics to identify members whose health is deteriorating before they become high‑cost patients. By integrating with existing care‑management infrastructure, CRTs deliver early, targeted interventions that reduce emergency...
Oncology Innovation Outpaces Managed Care’s Ability to Keep Up
Rapid advances in precision oncology are outpacing managed‑care systems, leaving gaps in biomarker testing, pharmacogenomics, CAR‑T access, and clinical pathway adherence. A study showed only 35.6% of eligible NSCLC patients receive targeted therapy, while DPYD testing—costing $175—could prevent $180,000‑plus in...
The Benefits of Cosmetic Dentistry for Long-Term Oral Health
The American Dental Association notes that 92% of adults have experienced cavities, prompting a reevaluation of cosmetic dentistry as a preventive tool. Modern procedures such as clear aligners, veneers, and crown lengthening not only improve appearance but also enhance tooth...
Ads for GLP-1 Drugs Are Flooding the Internet – Here’s How to Know if It’s Safe to Buy Them Online
The surge in online advertisements for GLP‑1 weight‑loss drugs, amplified by a high‑profile Super Bowl commercial, has led many consumers to seek cheaper, compounded versions of medications like Ozempic and Wegovy. The FDA warns that these non‑brand products often bypass...
Australian Bee Glue Delivers a Scar-Fighting Compound that Shuts Down Raised Scars Before They Take Hold
University of the Sunshine Coast researchers have isolated a natural compound, tomentosenol A, from the propolis of the Australian stingless bee Tetragonula carbonaria. Laboratory tests on human skin cells showed the molecule blocks scar‑forming signals and induces fibroblast self‑destruction, mimicking normal...
Six Tailored Keynote Narratives Shaping Healthcare's Future
This conference season, I work with six keynote narratives. I still customize each for every single event and audience, but the narratives (that I work on with a dedicated team for months) help tell a powerful story. Here they are: 01...
ARS Pharmaceuticals Reports Health Canada Approval of Neffy 2mg to Treat Type I Allergic Reactions
Health Canada has approved ARS Pharma’s neffy 2 mg adrenaline nasal spray for adults and children weighing over 30 kg, marking the first needle‑free emergency treatment for anaphylaxis in the country. In November 2024, ARS granted ALK exclusive rights to commercialize neffy...
New Study on AI Clinical Decision-Making
A recent study evaluated large language model (LLM) AIs across 29 clinical vignettes, generating 16,254 responses. Scores ranged from 0.64 for Gemini 1.5 Flash to 0.78 for Grok 4, with GPT models leading overall. While final‑diagnosis accuracy was modest, failure rates for differential...
MRNA Nanoparticles Teach Beta Cells to Prevent Type 1 Diabetes
As a medical school professor, I can tell you: what we've been doing for type 1 diabetes is managing, not curing. University of Chicago scientists just changed the game. They developed mRNA-loaded nanoparticles that deliver genetic instructions directly to insulin-producing beta cells,...
Elderly Can Harbor Amyloid Yet Remain Cognitively Normal
“ In this group of participants without clinically significant impairment, amyloid deposition was not associated with worse cognitive function, suggesting that an elderly person with a significant amyloid burden can remain cognitively normal.” Small sample size, but with numerous confirmatory studies...
My Recent Interview on RCR with Paul Brennan – Exposing the Machinery Behind the COVID Response and What's Coming Next
In this episode of RCR with Paul Brennan, investigative journalist Sonia Elijah discusses her new book, *3.11: Viral Takeover*, which offers a forensic timeline of the COVID‑19 response and the emergence of a global biodefense industrial complex. She highlights how...
Unexpected Lesson From an On‑call Hospital Night
A little break from talking about GLP-1s and obesity medicine. Here's a short story about when I was doing an on-call shift at the hospital a few years back:
Hospital at Home Evaluation Shows 80 Percent Cost Savings at West Hertfordshire Teaching Hospitals
West Hertfordshire Teaching Hospitals reported an 80% cost reduction for its Hospital at Home (HAH) program, saving £1.33 million (~$1.7 million) over a 12‑month period. The virtual care model cost $150 per bed day versus $723 for inpatient stays, cutting average length...
The Racist Patient, Revisited
Fifteen years after a resident’s essay about a racist patient went viral, health systems are finally naming and policing discriminatory behavior in clinical settings. Major institutions such as Cleveland Clinic, Mayo Clinic, Mass General Brigham and UCSF have introduced policies,...
Will Cancer Drugmakers Ever Conquer P53?
Elephants’ 20 copies of the TP53 gene give them a powerful p53‑driven cancer shield, while humans rely on a single copy that is frequently mutated. Restoring p53 function has long been labeled “undruggable,” leading to a string of high‑profile failures,...
American Academy of Nursing Issues Comprehensive AI Position Statement
On Feb. 25, 2026 the American Academy of Nursing (AAN) approved a comprehensive AI position statement that frames artificial intelligence as a collaborative tool to augment, not replace, nursing judgment. Developed by the Academy’s AI Taskforce, the document outlines 13 policy recommendations...
A Blunt Assessment of Every Major ACCESS Model Participant, Their Business Models, and What CMS’s New Outcome-Aligned Payment Framework Actually...
The CMS Innovation Center’s ACCESS Model launches July 5, 2026, testing an Outcome‑Aligned Payment (OAP) system for chronic‑care management across cardiometabolic, musculoskeletal and behavioral‑health tracks. Participants receive monthly fixed per‑patient payments, with half withheld until a 12‑month reconciliation that depends on meeting...
Radiology Business Management Association Elects New Board Members
The Radiology Business Management Association (RBMA) announced its new 2026‑2027 board at the annual PaRADigm meeting in Championsgate, Florida. Stacy Sanso, director of patient access at ARA Diagnostic Imaging, will serve as president, succeeding Jamie Dyer, who moves to immediate...
Today's Teen Could Become First 150‑year‑old
David Sinclair says the first person to live to 150 is a teenager who's alive today. He's taken flak from colleagues for years over this prediction. He doesn't care. He still stands by it. "The first person to live to 150 has...
FDA Panel to Consider Expanding Peptide Access
FDA panel will meet to discuss allowing broader access to certain peptides https://t.co/PDWKvmvvUH via @LizzyLaw_
Liverpool University Hospitals Announces 10-Year EPR Supplier
Liverpool University Hospitals NHS Foundation Trust has inked a 10‑year, £53 million (~$68 million) agreement with Nervecentre to deploy its electronic patient record (EPR) across Aintree, Broadgreen and Royal Liverpool hospitals. The deal brings roughly 1,600 beds onto a single, integrated digital...
AI Agents and Next‑Gen Alzheimer’s Drugs Beyond CRISPR
Endpoints' Drug Discovery Day is today — our own @RLCscienceboss will be talking about beyond CRISPR & future of Alzheimer's drugs I'm excited to talk with Stanford's @james_y_zou on his escalating research in building AI agents into co-scientists, labs, and now biotechs...
RVMD and ALLO Illustrate Biotech's Enduring Success Struggle
Why $RVMD & $ALLO are a microcosm of biotech's historic struggle for success. Some musings from me on @ApexOnco -> https://t.co/3lWgzQplvc
She Thinks Bad Medicine Killed Her Daughter. Six Years on, She’s Still Waiting for Answers
In early 2020, four Colombian children, including six‑year‑old Valery Javiana, died after receiving methotrexate injections contaminated with Pseudomonas aeruginosa from Naprod Life Sciences. Colombian regulator Invima identified the bacterial contamination but delayed a full product withdrawal, allowing the drug to...
Vaccines Don’t Cause Autism; Genetics Prove It
Writing garbage in CAPS doesn’t make it true. Not only do we have overwhelming scientific evidence that vaccines don’t cause autism, there’s also the complete lack of plausibility based on what we’ve learned about the >100 autism genes and how...
Afterburner Capital and Council Capital Exit Home Care Provider Advanced Care Partners
Afterburner Capital and Council Capital have exited their investments in Advanced Care Partners, a home‑care provider serving seniors across the United States. The firms did not disclose the transaction price or the identity of the buyer. The exit follows a...
Advisory Committee Needed to Vet RP1/Replimmune Melanoma Data
I haven’t dug into the specifics of the RP1/Replimmune data in melanoma, but isn’t this an example of where a good old-fashioned Adcomm could help vet the data and overall risk-benefit? https://t.co/qAxtU9pUeF
The Paradox of Modern Medicine
Diagnostic errors affect an estimated 13 million Americans each year, with over 750,000 resulting in permanent disability or death. Despite a 2015 National Academies report calling for reform, most U.S. health systems still lack systematic tracking of misdiagnoses, and only nine...
Energy Levels Reveal Early Healthspan Decline Signals
Energy isn't just a feeling. It may be one of the earliest biological windows into healthspan decline. New from @BuckInstitute's Healthspan Horizons, led by @NathanPriceSci, exploring how mitochondrial function, sleep, glucose stability, and inflammation converge as early warning signals. This matters for...
Anthropic's IPO Play, Novo Nordisk X OpenAI, and the First Brain Sensor Goes Human
The episode covers a rapid round‑up of AI‑related headlines: Apple is testing four frame designs for smart glasses that will focus on camera, call, and AI assistant functions rather than AR; Vercel’s CEO announced a surge to a $340 million ARR...
Tumor Microenvironment‐Responsive Dual‐Enzymatic Flasklike Nanobots for Enhanced Chemotherapy
Researchers have engineered a flask‑shaped nanobot (GC‑M@FPNbot) that harnesses glucose oxidase and catalase to self‑propel in response to tumor‑specific proton and hydrogen peroxide gradients. Loaded with doxorubicin, the bots exhibit chemotactic motion that enables deep penetration of extracellular matrix and...
Atelerix Forms Strategic Partnership With JH Health Ltd to Expand Non-Cryogenic Cell Preservation Capabilities in the Middle East
Atelerix, a UK biotech, has signed a strategic partnership with Saudi Arabia’s JH Health Ltd, granting JH Health exclusive rights to distribute Atelerix’s non‑cryogenic hydrogel cell‑preservation solutions across the Middle East. The deal includes funding for high‑volume local manufacturing, regulatory...
Navigated TMS Cuts Combat PTSD Symptoms for 85% in Landmark Trial
Researchers at UT Health San Antonio reported that a patented, MRI‑guided, robotic transcranial magnetic stimulation (TMS) protocol reduced PTSD symptoms in 85% of combat‑exposed service members and veterans when combined with intensive psychotherapy. The randomized trial, published in JAMA Network...